Imatinib
Small molecule targets ABL1, ABL2, BCR, CYP2D6, CYP3A4, KIT, PDGFRA, PDGFRB, SYK via inhibition
Regulatory milestones approvals, filings & regulatory actions · 20 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (17) | US (FDA) | GLEEVEC | — | 2002-02-01 – 2016-08-25 | fda.gov ↗ |
| Refused (EMA) | EU (EMA) | Ruvise | — | 2013-02-22 | europa.eu ↗ |
| Approved | EU (EMA) | Glivec | — | 2001-11-07 | europa.eu ↗ |
| Approved | US (FDA) | GLEEVEC | — | 2001-05-10 | fda.gov ↗ |
Trials 427 · started per year
Also used as a comparator or background therapy in 95 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03228303 Comparator | Dec 2017 → Jul 2020 | chronic myeloid leukemia | Assiut University | Unknown | No outcome recorded |
| Phase 112 trials | ||||||
| Phase 1 | NCT06889168 Comparator | Oct 2025 → Dec 2026 expected | lymphangioleiomyomatosis | Columbia University | Recruiting | No outcome recorded |
| Phase 1 | NCT06655246 Background | Mar 2025 → Dec 2027 expected | gastrointestinal stromal tumor | Kura Oncology, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05623774 Comparator | Dec 2022 → Jun 2024 | chronic myeloid leukemia | Inhibikase Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT03328117 Comparator | Nov 2017 → Mar 2018 | acute lung injury | Exvastat Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT02129166 Comparator | Sep → Oct 2014 | — | University of Florida | Withdrawn | No outcome recorded |
| Phase 1 | NCT02081378 Background | Apr 2014 → Jun 2021 | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2), chronic myeloid leukemia | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT01751425 Background | Jul 2013 → Sep 2019 | Philadelphia-positive myelogenous leukemia, chronic myeloid leukemia | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1 | NCT00686218 Background | May 2008 → Mar 2013 | leukemia | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00483366 Background | Aug 2006 → Jan 2009 | cancer of unknown primary site | University of Nebraska | Completed | No outcome recorded |
| Phase 1 | NCT00324077 Background | Aug 2006 → Feb 2007 | chronic myeloid leukemia | Bristol-Myers Squibb | Withdrawn | No outcome recorded |
| Phase 1 | NCT00301093 Background | Sep 2005 → May 2007 | leukemia | Dana-Farber Cancer Institute | Completed | No outcome recorded |
| Phase 1 | NCT00066326 Background | Jun 2003 → Oct 2004 | leukemia | Barbara Ann Karmanos Cancer Institute | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT04006847 Background | Sep 2020 → May 2021 | chronic myeloid leukemia | Milton S. Hershey Medical Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT02257541 Background | Oct 2014 → Mar 2019 | gastrointestinal stromal tumor | Memorial Sloan Kettering Cancer Center | Completed | No outcome recorded |
| Phase 1/2 | NCT01188889 Background | Sep 2013 → Dec 2016 | chronic myeloid leukemia | University of Michigan Rogel Cancer Center | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT00784446 Comparator | Apr 2008 → Aug 2010 | colorectal cancer | University of Cologne | Completed | No outcome recorded |
| Phase 1/2 | NCT00219765 Background | May 2001 → Jan 2006 | chronic myeloid leukemia | Poitiers University Hospital | Terminated | No outcome recorded |
| Phase 237 trials | ||||||
| Phase 2 | NCT07493408 Background | Mar 2026 → Dec 2035 expected | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2), blast phase chronic myelogenous leukemia, BCR-ABL1 positive, disease related to hematopoietic stem cell transplant | The University of Hong Kong | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05152472 Background | Jan 2022 → Oct 2027 expected | gastrointestinal stromal tumor | Centre Leon Berard | Recruiting | No outcome recorded |
| Phase 2 | NCT04838041 Background | Nov 2021 → Jun 2028 expected | chronic myeloid leukemia | Medical College of Wisconsin | Recruiting | No outcome recorded |
| Phase 2 | NCT06219733 Comparator | Jun 2021 → May 2022 | dermoid cyst | MedPacto, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT04794088 Comparator | Mar 2021 → Mar 2022 | COVID-19, acute respiratory distress syndrome, pulmonary edema | Dr. Jurjan Aman | Terminated | No outcome recorded |
| Phase 2 | NCT04688983 Comparator | Jan 2021 → Jan 2024 | adult acute lymphoblastic leukemia | Cardiff University | Unknown | No outcome recorded |
| Phase 2 | NCT04626024 Background | Dec 2020 → Nov 2028 expected | chronic myeloid leukemia | Baylor College of Medicine | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04126681 Comparator | Oct 2019 → Aug 2024 | chronic myeloid leukemia | Ascentage Pharma Group Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03906292 Background | Aug 2019 → Dec 2027 expected | chronic myeloid leukemia | University of Jena | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03516279 Background | Jun 2019 → Aug 2028 expected | chronic myeloid leukemia | ECOG-ACRIN Cancer Research Group | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03389256 Background | Dec 2018 → Dec 2020 | non-small cell lung carcinoma | Sichuan Cancer Hospital and Research Institute | Unknown | No outcome recorded |
| Phase 2 | NCT03654768 Background | Oct 2018 → Jul 2024 overdue | chronic myeloid leukemia | SWOG Cancer Research Network | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04883125 Comparator | Jan 2018 → Apr 2021 | Philadelphia-positive myelogenous leukemia, chronic myeloid leukemia | Mansoura University | Completed | No outcome recorded |
| Phase 2 | NCT02687425 Background | Feb → Nov 2016 | chronic myeloid leukemia | Meng Li | Unknown | No outcome recorded |
| Phase 2 | NCT02001818 Background | Apr 2014 → Jan 2022 | chronic myeloid leukemia | Australasian Leukaemia and Lymphoma Group | Completed | No outcome recorded |
| Phase 2 | NCT01593254 Comparator | Sep 2012 → Nov 2017 | chronic myeloid leukemia | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 2 | NCT01429610 Background | Nov 2011 → Jan 2018 | precursor lymphoblastic lymphoma/leukemia | Asan Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT01503502 Comparator | Aug 2011 → Jun 2012 | chronic myeloid leukemia | Jiangsu HengRui Medicine Co., Ltd. | Unknown | No outcome recorded |
| Phase 2 | NCT01312818 Background | Jun 2011 → Jan 2013 | acute lymphoblastic leukemia | Masonic Cancer Center, University of Minnesota | Terminated | No outcome recorded |
| Phase 2 | NCT01097694 Comparator | Nov 2010 → Aug 2015 | asthma | Brigham and Women's Hospital | Completed | No outcome recorded |
| Phase 2 | NCT01227135 Background | Mar 2010 → Mar 2012 | leukemia | Lynn McMahon | Unknown | No outcome recorded |
| Phase 2 | NCT01011998 Background | Sep 2009 → Jun 2010 | chronic myeloid leukemia | New Mexico Cancer Research Alliance | Withdrawn | No outcome recorded |
| Phase 2 | NCT01005914 Background | Jun 2009 → Mar 2013 | leukemia | OHSU Knight Cancer Institute | Terminated | No outcome recorded |
| Phase 2 | NCT00882206 Background | Apr 2009 → Jan 2013 | leukemia, lymphoma | Masonic Cancer Center, University of Minnesota | Terminated | No outcome recorded |
| Phase 2 | NCT00852566 Comparator | Mar 2009 → Feb 2011 | chronic myeloid leukemia | Norwegian University of Science and Technology | Completed | No outcome recorded |
| Phase 2 | NCT01089595 Comparator | Feb 2009 → Nov 2011 | gastrointestinal stromal tumor, metastatic neoplasm | Fox Chase Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT00427999 Background | Feb 2007 → Jun 2015 | prostate cancer | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00415909 Background | Dec 2006 → May 2013 | chronic myeloid leukemia | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT00415857 Background | Dec 2006 → Sep 2013 | leukemia | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 2 | NCT00320190 Comparator | Aug 2006 → Jan 2010 | chronic myeloid leukemia | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 2 | NCT00455559 Background | Aug 2006 → Nov 2010 | gastrointestinal stromal tumor | AEterna Zentaris | Completed | No outcome recorded |
| Phase 2 | NCT00110058 Background | Feb 2005 → Jul 2006 | leukemia | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01227356 Background | Sep 2004 → Mar 2009 | — | Uppsala University | Completed | No outcome recorded |
| Phase 2 | NCT00209079 Comparator | Sep 2004 → Apr 2007 | gastric adenocarcinoma | Emory University | Terminated | No outcome recorded |
| Phase 2 | NCT00154336 Comparator | Jul 2004 → Aug 2005 | rheumatoid arthritis | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT00058747 Background | Mar 2003 → Apr 2006 | chronic myeloid leukemia | Agenus Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00036738 Background | Jul 2001 → Jul 2014 | B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2), adult acute lymphoblastic leukemia, blast phase chronic myelogenous leukemia, BCR-ABL1 positive, childhood acute lymphoblastic leukemia | Fred Hutchinson Cancer Center | Completed | No outcome recorded |
| Phase 334 trials | ||||||
| Phase 3 | NCT06821542 Background | Jun 2025 → May 2028 expected | chronic graft versus host disease | Incyte Corporation | Active not recruiting | No outcome recorded |
| Phase 3 | NCT06682169 Comparator | Nov 2024 → Oct 2029 expected | chronic graft versus host disease | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT04971226 Comparator | Oct 2021 → Nov 2023 overdue | chronic myeloid leukemia | Novartis Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04722848 Comparator | Sep 2021 → Sep 2027 expected | adult acute lymphoblastic leukemia | GIMEMA Foundation | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03722420 Comparator | Dec 2018 → Mar 2023 overdue | chronic myeloid leukemia | Il-Yang Pharm. Co., Ltd. | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03589326 Comparator | Oct 2018 → Aug 2022 overdue | acute lymphoblastic leukemia | Takeda | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03639922 Comparator | Oct 2018 → Dec 2022 | ischemic stroke | Niaz Ahmed | Unknown | No outcome recorded |
| Phase 3 | NCT03515018 Comparator | May 2018 → May 2020 | chronic myeloid leukemia | First Affiliated Hospital of Harbin Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT03112603 Comparator | Jun 2017 → May 2020 | chronic graft versus host disease | Incyte Corporation | Completed | No outcome recorded |
| Phase 3 | NCT02576080 Comparator | Oct 2015 → Oct 2019 | gastrointestinal stromal tumor | Assistance Publique Hopitaux De Marseille | Unknown | No outcome recorded |
| Phase 3 | NCT02272777 Comparator | Jul 2014 → Jan 2017 | leukemia | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02130557 Comparator | Jul 2014 → Aug 2016 | chronic myeloid leukemia | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT02204644 Comparator | Jun 2014 → Jun 2017 | chronic myeloid leukemia | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01755325 Background | Nov 2012 → Dec 2018 | chronic myeloid leukemia | Junmin Li | Suspended | No outcome recorded |
| Phase 3 | NCT01650805 Comparator | Jun 2012 → Oct 2013 | chronic myeloid leukemia | Ariad Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT01511289 Comparator | Aug 2011 → Feb 2015 | Philadelphia-positive myelogenous leukemia, chronic myeloid leukemia | Il-Yang Pharm. Co., Ltd. | Completed | No outcome recorded |
| Phase 3 | NCT01275196 Comparator | Apr 2011 → Oct 2014 | chronic myeloid leukemia | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01031628 Comparator | Jan 2010 → Jun 2011 | gastrointestinal stromal tumor | Sarcoma Alliance for Research through Collaboration | Terminated | No outcome recorded |
| Phase 3 | NCT00760877 Comparator | Jun 2009 → Jul 2015 | chronic myeloid leukemia | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00751036 Comparator | Jun 2009 → Aug 2012 | gastrointestinal stromal tumor | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT00802841 Comparator | May 2009 → Jul 2014 | chronic myeloid leukemia | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00956072 Comparator | May 2009 → Mar 2011 | gastrointestinal stromal tumor | European Organisation for Research and Treatment of Cancer - EORTC | Terminated | No outcome recorded |
| Phase 3 | NCT00785785 Comparator | Mar 2009 → Oct 2014 | gastrointestinal stromal tumor | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00812240 Comparator | Jan 2009 → Jul 2018 | gastrointestinal stromal tumor | AB Science | Terminated | No outcome recorded |
| Phase 3 | NCT01400074 Comparator | Jan 2009 → Jun 2014 | chronic myeloid leukemia | Seoul St. Mary's Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT01460693 Comparator | Aug 2008 → Mar 2018 | chronic myeloid leukemia | Newcastle University | Completed | No outcome recorded |
| Phase 3 | NCT00574873 Comparator | Feb 2008 → Aug 2010 | chronic myeloid leukemia | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00519090 Comparator | Oct 2007 → Oct 2008 | myeloid leukemia | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT00481247 Comparator | Sep 2007 → Dec 2009 | chronic myeloid leukemia | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00372567 Comparator | Jun 2007 → Nov 2009 | gastrointestinal stromal tumor | Pfizer | Terminated | No outcome recorded |
| Phase 3 | NCT00362466 Comparator | Apr 2007 → Jun 2008 | leukemia | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 3 | NCT00471328 Background | Mar 2007 → Aug 2008 | gastrointestinal stromal tumor | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00116935 Comparator | Feb 2004 → Dec 2010 | sarcoma | Scandinavian Sarcoma Group | Completed | No outcome recorded |
| Phase 3 | NCT00050531 Background | Apr 2003 → Apr 2007 | chronic myeloid leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 44 trials | ||||||
| Phase 4 | NCT05367765 Comparator | Apr 2022 → Apr 2027 expected | chronic myeloid leukemia | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT05071482 Comparator | Sep 2021 → Jan 2023 | acute leukemia | Institute of Hematology & Blood Diseases Hospital, China | Terminated | No outcome recorded |
| Phase 4 | NCT01578213 Background | Nov 2011 → Nov 2018 | chronic myeloid leukemia | University of Milano Bicocca | Completed | No outcome recorded |
| Phase 4 | NCT00510354 Background | Oct 2006 → Nov 2012 | gastrointestinal stromal tumor | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT05751733 Comparator | Feb 2023 → Jan 2026 overdue | gastrointestinal stromal tumor | Xiangya Hospital of Central South University | Recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT01085617 Background | Dec 2010 → Feb 2025 | leukemia, mouth disorder, mucositis | University College, London | Completed | No outcome recorded |
Press releases naming this drug 9 releases
| Date | Issuer | Release |
|---|---|---|
| 2017-01-25 | Novartis Pharmaceuticals | Novartis delivered solid 2016 performance, with Growth Products[1] absorbing Gleevec US LOE; innovation momentum continued; announces share buyback novartis.com ↗ |
| 2016-12-05 | Novartis Pharmaceuticals | Novartis data shows Treatment-free Remission rates are consistently above 50% regardless of reason for switch to Tasigna® from Glivec® novartis.com ↗ |
| 2016-10-31 | Novartis Pharmaceuticals | Novartis Wins Two Prestigious Prix Galien Foundation Awards; Gleevec® recognized as "Discovery of the Decade" for Best Pharmaceutical Product, Cosentyx® as Best Biotechnology Product novartis.com ↗ |
| 2016-10-25 | Novartis Pharmaceuticals | Novartis delivered solid third quarter with Growth Products[1] offsetting Gleevec patent expiration; several positive readouts for potential blockbusters novartis.com ↗ |
| 2016-08-05 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Launch of Generic Gleevec® Tablets in the United States tevapharm.com ↗ |
| 2016-07-19 | Novartis Pharmaceuticals | Novartis delivered solid Q2 despite full quarter of US Gleevec generic impact; significant positive innovation news strengthens future growth prospects novartis.com ↗ |
| 2016-04-21 | Novartis Pharmaceuticals | Novartis delivered solid Q1 despite Gleevec loss of exclusivity; investing behind new launches for long-term growth novartis.com ↗ |
| 2010-12-07 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Follow-Up Results from Study Comparing SPRYCEL (dasatinib) to Imatinib in First-Line Treatment of Adults with Ph+ CP-CML Demonstrate Improved Response Rates Consistent with 12 Month Data®*1 otsuka.co.jp ↗ |
| 2010-06-09 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Four-Year Follow-Up Data for SPRYCEL (dasatinib) Demonstrate 82 Percent Overall Survival in Patients with Chronic Myeloid Leukemia Who Failed Gleevec®®* otsuka.co.jp ↗ |
Evidence & citations 27 cited values
Every value below carries the sentence it was read from. 544 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Imatinib | “Control chemotherapy treatment will be chosen from any of the following standard-of-care chemotherapy drugs or combinations:
* Carboplatin;
* Irinotecan;
* Etoposide;
*...” NCT03632135 ↗384“Five patients who are on treatment of imatinib and deriving clinical benefit after CAMN107DBR01 study termination and written informed consent obtained will enter the trial,...” NCT01613053 ↗ “This is a randomised, double-blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, and PK of single and multiple inhaled doses of imatinib...” NCT04903730 ↗ “Imatinib has exceptional activity in controlling gastrointestinal stromal tumor (GIST) due to inhibition of the constitutively active conformation of KIT and PDGFRA which is...” PMID 21140148 ↗ Dec 2010 “* Imatinib: 400 mg/dose; orally once daily; duration of treatment 14 days. This is the standard maintenance dose which is at the lower end of that used for several years in the...” NCT05273242 ↗ “Participants received either the reference (4 tablets of 100-mg imatinib) or the test (1 tablet of 400-mg imatinib) formulation during the first period and the alternative...” PMID 24060561 ↗ Sep 2013 “Phase II Study to Evaluate the Efficacy of a Chemotherapy Combination With Imatinib (Glivec®) and 5-FU/Leucovorin in Patients With Advanced Carcinoma of the Gallbladder and Bile Duct” NCT01153750 ↗ “With the BCR/ABL protein TKI, imatinib, in the combination chemotherapy regimes for newly diagnosed Ph+ ALL, more than 95% of patients can achieve complete remission(CR).” NCT01883219 ↗ “Imatinib Mesylate (Glivec) as Maintenance Therapy After Cytogenetic Response With Nilotinib (AMN107, Tasigna) First Line in Newly Diagnosed Chronic Myelogenous Leukemia” NCT01316250 ↗ “This study is an open-label, multicenter, Phase I dose-escalation study of the combination of AMN107 and imatinib (STI571) in patients with imatinib-resistant GIST.” NCT00135005 ↗ “Low dose tyrosine kinase inhibitor (lowTKI) (dasatinib 50 mg daily or imatinib 300 mg daily or nilotinib 300 mg daily) at investigators discretion” NCT05143840 ↗ “All patients with Philadelphia positive ALL will be treated in this group and will receive a standard imatinib-containing chemotherapy regimen” NCT01616238 ↗ “This study will assess the pharmacokinetics of imatinib in pediatric patients ages 1 to \<4 years of age to help develop dosing regimens” NCT01066468 ↗ “Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas” NCT01673009 ↗ “Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase” NCT00538109 ↗ “The registered dose for imatinib is 400 mg/d, despite high inter-patient variability in imatinib plasmatic exposure.” PMID 36015302 ↗ Aug 2022 “Participants will take Imatinib mesylate (imatinib), an FDA approved drug for leukemia, orally 400 mg (twice daily)” NCT06889168 ↗ “Imatinib or sunitinib can be administered at the last tolerated dose and regimen or at the Investigator's choice.” NCT00471328 ↗ “Imatinib was initiated at a dose of 200mg/d, dasatinib at a dose of 50mg/d, and ponatinib at a dose of 30mg/d.” NCT03624530 ↗ “In 2003 imatinib was introduced as a single-agent course following induction (N = 86, late imatinib).” PMID 24277073 ↗ Nov 2013 “Imatinib tablets, 125 mg tid po; gefitinib tablets, 250 mg qd po; erlotinib tablets, 150 mg qd po” NCT03389256 ↗ “tyrosine kinase inhibitor imatinib mesylate (formerly STI 571, GLIVEC, Novartis Pharma)” NCT00514488 ↗ “The BCR-ABL TKIs that will be used include imatinib, dasatinib, nilotinib or bosutinib.” NCT03610971 ↗ “Patients on this study will take 400 mg of imatinib twice daily (morning and evening).” NCT00038649 ↗ “Patients received imatinib (400 mg) plus pioglitazone (15 mg) daily for six months” PMID 41735647 ↗ Feb 2026 “Glivec® (Imatinib, Formerly Known as STI571) to Produce a Biochemical Response” NCT01316458 ↗ “Imatinib, a drug already proven safe in cancer treatment for over two decades” NCT07559370 ↗ “Megavec 400 mg (Imatinib Mesylate) in Healthy Adult Male Volunteers” NCT01653314 ↗ “AV-101 (imatinib) administered via dry powder inhalation” NCT05036135 ↗ “Gleevec (Imatinib Mesylate, STI571) Maintenance Therapy” NCT00156286 ↗ “These were combined with 400 mg QD imatinib.” PMID 35524239 ↗ May 2022 “Patients received imatinib 400 mg/day.” PMID 20220063 ↗ Mar 2010 “Imatinib 400 mg once a day for 4 weeks” NCT04644432 ↗ “Ifosfamide, Imatinib, Irinotecan” NCT02788201 ↗ “Hydroxyurea Imatinib Irinotecan” NCT02551718 ↗ “Imatinib 800mg/d during 14days” NCT04357613 ↗ “Imatinib 600mg/d po qd” NCT01429610 ↗ “imatinib,0.4g,qd” NCT01755325 ↗ “Imatinib 400mg” NCT01504984 ↗ “• Imatinib” NCT06821542 ↗ “• Imatinib” NCT07124078 ↗ “Imatinib” NCT00386373 ↗ “Imatinib” NCT00027586 ↗ “Imatinib” NCT04006847 ↗ “Imatinib” NCT04817956 ↗ “Imatinib” NCT02142036 ↗ |
| Known as | AV-101 | “AV-101 (imatinib) administered via dry powder inhalation” NCT05036135 ↗ |
| Known as | Gleevec | “A Randomized Multi-Center Open Label Study of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjects With Chronic Phase Philadelphia Chromosome-Positive Chronic...” NCT00103844 ↗60“A Phase I/II Study to Determine Safety and Efficacy of Arsenic Trioxide (Trisneox™) in Combination With Imatinib (STI571, Gleevec™) in Patients With Chronic Myelogenous...” NCT00081133 ↗ “The purpose of this study is to evaluate the safety and efficacy of the tyrosine kinase inhibitor, imatinib mesylate (Gleevec ) in reducing peripheral blood eosinophilia in...” NCT00044304 ↗ “A Phase I-II, Study of RAD001 in Combination With Imatinib (Glivec®/Gleevec™) in Patients With Chronic Myelogenous Leukemia (CML) in Chronic Phase Who Are Not In Complete...” NCT00093639 ↗ “Phase I: To determine the maximum tolerated doses, toxicities, and pharmacokinetics of imatinib mesylate (Gleevec) in patients with malignant gliomas taking enzyme-inducing...” PMID 16914578 ↗ Aug 2006 “The purpose of the study is to find out what effects (good and bad) Gleevec® (Imatinib mesylate) combined with chemotherapy has on participants and their acute myeloid leukemia.” NCT00955916 ↗ “The identification of KIT+ tumor has become more important after introduction of target treatment with KIT tyrosine kinase inhibitor Imatinib mesylate (Gleevec).” NCT00290485 ↗ “A Phase II Pilot Study to Determine the Safety and Preliminary Efficacy of Imatinib Mesylate (Gleevec) in Patients With Myelofibrosis With Myeloid Metaplasia” NCT00245128 ↗ “A Phase I Trial of Imatinib Mesylate (Gleevec, Formerly Known as STI571) in Combination With Daunorubicin and Cytarabine for C-kit Positive Relapsed AML” NCT00268229 ↗ “Imatinib mesylate (STI571 or Gleevec) is a specific inhibitor of the fusion protein Bcr-Abl, the causal agent in chronic myelogenous leukaemia.” NCT00573326 ↗ “Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase” NCT00538109 ↗ “Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas” NCT01673009 ↗ “Long-term safety and efficacy of imatinib mesylate (Gleevec®) in elderly patients with chronic phase chronic myelogenous leukemia” PMID 22987312 ↗ Sep 2012 “Phase I Study Of Flavopiridol In Combination With Imatinib Mesylate (STI571, Gleevec) In Bcr/Abl+ Hematological Malignancies” NCT00064285 ↗ “A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors.” PMID 20530436 ↗ Apr 2010 “A Phase II Trial of Gemzar (Gemcitabine) and Gleevec (Imatinib Mesylate) in Patients With Metastatic Renal Cell Carcinoma” NCT00323791 ↗ “higher doses of imatinib mesylate (Gleevec, STI571) can improve chronic myelogenous leukemia (CML) in chronic phase.” NCT00038649 ↗ “Imatinib (Gleevec) in Combination With Irinotecan and Cisplatin in Extensive Stage Small Cell Lung Cancer” NCT00045604 ↗ “Imatinib mesylate (Gleevec/Glivec, IM) is currently the gold standard or CML-CP front line therapy.” NCT02896842 ↗ “Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)” NCT00867113 ↗ “Imatinib Mesylate (Gleevec®, STI571) in Combination With Docetaxel (Taxotere)” NCT00216112 ↗ “Imatinib (Gleevec) or high dose Interferon (Intron) in treating melanoma” NCT01782508 ↗ “Imatinib Mesylate (Gleevec; STI571), A PDGFR And C-Kit Inhibitor” NCT00039585 ↗ “imatinib mesylate (Gleevec) in patients with systemic sclerosis” NCT00555581 ↗ “Gleevec (Imatinib Mesylate, STI571) Maintenance Therapy” NCT00156286 ↗ “Imatinib Mesylate (Gleevec®; STI571; NSC #716051)” NCT01991379 ↗ “Gleevec (also called imatinib mesylate).” NCT00183833 ↗ “Gleevec (imatinib), valproic acid” NCT01011998 ↗ “Imantinib Mesylate (Gleevec)” NCT00045422 ↗ “Gleevec (Imatinib Mesylate)” NCT00354523 ↗ “Imatinib Mesylate (Gleevec)” NCT00038675 ↗ “imatinib mesylate (Gleevec)” NCT00258271 ↗ “Gleevec (imatinib mesylate)” NCT00114959 ↗ “Imatinib Mesylate (Gleevec)” NCT00066326 ↗ “Gleevec (imatinib mesylate)” NCT00038194 ↗ “imatinib (Gleevec)” NCT02413736 ↗ “Imatinib (Gleevec)” NCT01126814 ↗ “Gleevec (imatinib)” NCT00314873 ↗ “Imatinib (Gleevec)” NCT00881049 ↗ “Imatinib (Gleevec)” NCT07406633 ↗ |
| Known as | Gleevec(Registered Trademark) | “This study will evaluate the safety and effectiveness of imatinib (Gleevec(Registered Trademark)) in patients with chronic myelomonocytic leukemia (CMML) and atypical chronic...” NCT00079313 ↗ |
| Known as | Gleevec-Imatinib-Imatinib mesylate | “Gleevec-Imatinib-Imatinib mesylate” NCT00613132 ↗ |
| Known as | Gleevec:Imatinib Mesylate | “Gleevec (imatinib mesylate)” NCT00558961 ↗ |
| Known as | Glevec | “Imatinib 600mg/day (Glevec is the brand name for imatinib)” NCT01275222 ↗ |
| Known as | Glinib | “A Phase IV Study to Evaluate Efficacy and Safety of Imatinib(Glinib®) 600mg/Day Depending on Early Molecular Response in Newly Diagnosed Patients With Chronic Myeloid Leukemia...” NCT02204722 ↗ |
| Known as | Glivec | “An Exploratory Single Center Study of High-dose Treatment of Glivec® in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP)...” NCT01216085 ↗29“Glivec (Imatinib) in Locally Advanced and/or Metastatic Soft Tissue Sarcomas Expressing the t(17;22)(q22;q13) Translocation Resulting in a COL1A1/PDGF-beta Fusion Protein i.e....” NCT00085475 ↗ “Intermediate and High Risk Localized, Completely Resected, Gastrointestinal Stromal Tumors (GIST) Expressing KIT Receptor: A Controlled Randomized Trial on Adjuvant Imatinib...” NCT00103168 ↗ “A Phase I-II, Study of RAD001 in Combination With Imatinib (Glivec®/Gleevec™) in Patients With Chronic Myelogenous Leukemia (CML) in Chronic Phase Who Are Not In Complete...” NCT00093639 ↗ “Open-Label Trial of Neoadjuvant Imatinib Mesylate (Glivec) in Patients With Locally Advanced Malignant Gastrointestinal Stromal Tumors (GIST) Expressing c-Kit or...” NCT00112632 ↗ “Phase II Study of Imatinib (Glivec) Administered as a Daily Oral Treatment in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck Overexpressing KIT” NCT00180921 ↗ “Imatinib (either Glivec® or any generic form) : Tyrosine Kinase Inhibitor (BCR-ABL, ABL, KIT and PDGFRA receptor tyrosine kinases); oral : 400 mg/day during at least 30 months” NCT04070443 ↗ “Imatinib Mesylate (Glivec) as Maintenance Therapy After Cytogenetic Response With Nilotinib (AMN107, Tasigna) First Line in Newly Diagnosed Chronic Myelogenous Leukemia” NCT01316250 ↗ “The purpose of this study is to assess the clinical anti-proliferative activity of STI571 (Glivec®, Novartis, Pharma) in patients with HES defined as:” NCT00276926 ↗ “Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase” NCT00538109 ↗ “Imatinib mesylate (Gleevec/Glivec, IM) is currently the gold standard or CML-CP front line therapy.” NCT02896842 ↗ “tyrosine kinase inhibitor imatinib mesylate (formerly STI 571, GLIVEC, Novartis Pharma)” NCT00514488 ↗ “Glivec® (Imatinib mesylate, formerly known as STI 571) plus Gemzar® (Gemcitabine)” NCT00551252 ↗ “Recent publications have suggested that imatinib (Glivec) may be cardiotoxic.” PMID 17336514 ↗ Mar 2007 “Glivec (Imatinib Mesylate) in the Treatment of Polycythemia Vera” NCT00430066 ↗ “tyrosine kinase inhibitor STI 571 (GLIVEC, Novartis Pharma)” NCT00511121 ↗ “Imatinib Mesylate STI571 (Glivec®) Versus Placebo” NCT00479934 ↗ “Glivec® (Imatinib Mesylate, STI571)” NCT00390897 ↗ “Imatinib mesylate 100 mg (Glivec)” NCT00845221 ↗ “Imatinib mesylate (Glivec)” NCT00278876 ↗ “Imatinib Mesilate (Glivec)” NCT00510926 ↗ “Imatinib (Glivec)” NCT00122473 ↗ |
| Known as | GLIVECÔ | “tyrosine kinase inhibitor imatinib mesylate (formerly STI 571, GLIVECÔ, Novartis Pharma)” NCT00510926 ↗ |
| Known as | IMA | “We profiled peripheral blood cell transcriptomes at imatinib (IMA) discontinuation in patients from the multicenter STIM2 trial (n = 96) to develop a transcriptome-based model...” PMID 42454992 ↗ Jun 2026 |
| Known as | Imatinib (STI571): Gleevec | “Imatinib (STI571): Gleevec” NCT01400074 ↗ |
| Known as | imatinib mesilate | “Over-encapsulated 100 mg imatinib mesilate tablets” NCT03328117 ↗ |
| Known as | imatinib mesylate | “Systemic sclerosis (SSc) is an autoimmune disease in which the tyrosine kinases platelet-derived growth factor receptor (PDGFR) and Abl are hypothesized to contribute to the...” PMID 19180499 ↗ Feb 2009195“A Randomized Multi-Center Open Label Study of BMS-354825 vs. Imatinib Mesylate (Gleevec) 800 mg/d in Subjects With Chronic Phase Philadelphia Chromosome-Positive Chronic...” NCT00103844 ↗ “The purpose of this study is to evaluate the safety and efficacy of the tyrosine kinase inhibitor, imatinib mesylate (Gleevec ) in reducing peripheral blood eosinophilia in...” NCT00044304 ↗ “The purpose of this study is to determine whether Imatinib Mesylate is active in diseases - such as Desmoid Tumor and Chondrosarcoma - expressing the receptor for the...” NCT00928525 ↗ “Imatinib mesylate (trade names: Glivec® and Gleevec®, imatinib, formerly STI571) is a signal transduction inhibitor targeting several protein-tyrosine kinases that are believed...” NCT01172548 ↗ “AIMS: Imatinib mesylate, as add-on therapy in patients with pulmonary arterial hypertension (PAH) who remain inadequately treated despite receiving at least two PAH-specific...” PMID 24566799 ↗ Feb 2014 “An exploratory study to examine the efficacy and safety of imatinib mesylate in combination with dihydroartemisinin plus piperaquine on suppression of parasitemia in patients...” NCT02614404 ↗ “Phase I: To determine the maximum tolerated doses, toxicities, and pharmacokinetics of imatinib mesylate (Gleevec) in patients with malignant gliomas taking enzyme-inducing...” PMID 16914578 ↗ Aug 2006 “To determine the maximum tolerable dose and assess the safety and tolerability of imatinib mesylate in combination with capecitabine and cisplatin in patients with unresectable...” NCT00601510 ↗ “To identify the maximum tolerated dose of imatinib (imatinib mesylate) in patients with recurrent oligodendroglioma and mixed oligoastrocytoma that are currently on enzyme...” NCT00049127 ↗ “Imatinib mesylate is a potent inhibitor of platelet-derived growth factor and transforming growth factor-β signalling pathways which may play a role in systemic sclerosis...” PMID 23039171 ↗ Oct 2012 “Open-label Multicenter Trial of Glivec® (Imatinib Mesylate, Formerly Known as STI571) in Combination With Chemotherapy (MTC) in Patients With Refractory or Relapsed Acute...” NCT00744081 ↗ “Imatinib mesylate (Gleevec), a clinically used PDGF receptor (PDGFR) tyrosine kinase inhibitor could be a promising molecular targeted approach to limit the liver fibrosis development.” NCT05224128 ↗ “This is a Phase III study comparing Imatinib mesylate and hydroxyurea combination therapy with hydroxyurea monotherapy in patients with temozolomide resistant progressive glioblastoma.” NCT00154375 ↗ “The purpose of this trial is to evaluate the use of long term adjuvant imatinib mesylate in patients at significant risk for recurrence following complete resection of primary GIST.” NCT00867113 ↗ “Patients also receive oral imatinib mesylate daily continually for one week prior to, during, and after chemotherapy in the absence of disease progression or unacceptable toxicity.” NCT00052494 ↗ “The purpose of this trial is to test the combination of Gleevec® (also known as imatinib mesylate) and Taxotere (also known as docetaxel) in patients with incurable stomach cancer.” NCT00209079 ↗ “Imatinib mesylate (referred to in this protocol as imatinib) is an inhibitor of the BCR-ABL kinase and been the standard first-line therapy for patients with chronic-phase CML.” NCT02130557 ↗ “Imatinib mesylate given orally at a daily dose of 400 mg is the standard of care as initial therapy for patients with chronic myeloid leukemia (CML) in chronic phase (CML-CP).” PMID 19117345 ↗ Feb 2009 “The identification of KIT+ tumor has become more important after introduction of target treatment with KIT tyrosine kinase inhibitor Imatinib mesylate (Gleevec).” NCT00290485 ↗ “Imatinib mesylate, a small-molecule inhibitor of the KIT tyrosine kinase, provides a rapid but not durable clinical response in KIT-mutant melanoma.” PMID 34889232 ↗ Dec 2021 “Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by stopping blood flow to the tumor.” NCT00084513 ↗ “Imatinib mesylate inhibits several tyrosine kinases involved in the fibrotic reaction, which is one of the main pathogenetic components of NSF.” NCT00981942 ↗ “Imatinib mesylate (STI571 or Gleevec) is a specific inhibitor of the fusion protein Bcr-Abl, the causal agent in chronic myelogenous leukaemia.” NCT00573326 ↗ “Imatinib Mesylate, 400 mg once daily, oral. 5 years of adjuvant imatinib treatment (standard treatment 3years + IP treatment : 2yesrs)” NCT05385549 ↗ “Patients receive oral imatinib mesylate once daily and arsenic trioxide IV over 1-2 hours on days 1-5 of week 1 and then twice weekly.” NCT00053248 ↗ “Arm I: Patients receive low-dose oral imatinib mesylate once daily in the absence of disease progression or unacceptable toxicity.” NCT00685828 ↗ “Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas” NCT01673009 ↗ “Efficacy and Tolerability of STI571 (Imatinib Mesylate) for the Treatment of Fibrosis in Participants With Systemic Sclerosis” NCT00613171 ↗ “Patients receive oral imatinib mesylate daily and decitabine IV over 1 hour daily, 5 days per week, for 2 consecutive weeks.” NCT00054431 ↗ “A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors.” PMID 20530436 ↗ Apr 2010 “RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for cancer cell growth.” NCT00031915 ↗ “RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth.” NCT00062205 ↗ “RATIONALE: Imatinib mesylate may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.” NCT01227135 ↗ “Intravenous Imatinib Mesylate solution- 200mg as an 8mg/ml solution, administered twice daily (400mg total daily dose).” NCT04953052 ↗ “Effect of Antacids (Mg-Al-based) on Imatinib Mesylate (Gleevec®) Pharmacokinetics in Healthy Volunteers (CSTI571BUS257)” NCT00446316 ↗ “RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth.” NCT00085475 ↗ “Nilotinib 300 mg orally twice per day for 12 months followed by imatinib mesylate at a dose of 400 mg orally daily” NCT01316250 ↗ “Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study.” PMID 23403476 ↗ Feb 2013 “Phase II Study of Gleevec (Imatinib Mesylate) in Patients With Idiopathic Hypereosinophilic Syndrome (HES)” NCT00230334 ↗ “Imatinib Mesylate is a new medication that blocks several proteins important in the development of cancer.” NCT00510653 ↗ “Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for their growth.” NCT00093639 ↗ “Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for their growth.” NCT00081133 ↗ “Once daily oral administration of STI571 (imatinib mesylate) at a dose of 400 mg or 600mg for 12 months.” NCT00015847 ↗ “Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth.” NCT00080665 ↗ “Treatment: Imatinib mesylate is a new oral medication that blocks a protein that is responsible for CML” NCT01092741 ↗ “Imatinib mesylate (Gleevec/Glivec, IM) is currently the gold standard or CML-CP front line therapy.” NCT02896842 ↗ “Once daily oral administration of STI571 (Imatinib Mesylate) at a dose of 400 mg for 12 months.” NCT00022490 ↗ “Imatinib mesylate is the standard therapy for CML and blocks the function of this protein.” NCT00267085 ↗ “tyrosine kinase inhibitor imatinib mesylate (formerly STI 571, GLIVECÔ, Novartis Pharma)” NCT00510926 ↗ “tyrosine kinase inhibitor imatinib mesylate (formerly STI 571, GLIVEC, Novartis Pharma)” NCT00514488 ↗ “Glivec® (Imatinib mesylate, formerly known as STI 571) plus Gemzar® (Gemcitabine)” NCT00551252 ↗ “one-week on and one-week off schedule(Imatinib Mesylate, 400 mg once daily, oral)” NCT02712112 ↗ “Imatinib mesylate 400 mg orally twice daily was administered on day 2 to day 15.” NCT00955916 ↗ “Imatinib mesylate is the first line treatment for chronic myeloid leukemia.” PMID 18838477 ↗ Oct 2008 “Imatinib mesylate (which you are already receiving as standard therapy).” NCT00415857 ↗ “Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients” NCT00386373 ↗ “Megavec 400 mg (Imatinib Mesylate) in Healthy Adult Male Volunteers” NCT01653314 ↗ “Patients receive oral imatinib mesylate once daily on days 1-28.” NCT00068783 ↗ “Glivec (Imatinib Mesylate) in the Treatment of Polycythemia Vera” NCT00430066 ↗ “Patients receive oral imatinib mesylate once daily on days 1-28.” NCT00039585 ↗ “Patients receive oral imatinib mesylate once or twice daily.” NCT00039364 ↗ “Gleevec (Imatinib Mesylate, STI571) Maintenance Therapy” NCT00156286 ↗ “Patients receive oral imatinib mesylate twice daily.” NCT00045188 ↗ “Imatinib Mesylate (Gleevec®; STI571; NSC #716051)” NCT01991379 ↗ “either imatinib (imatinib mesylate) or rituximab” NCT01309997 ↗ “Gleevec (also called imatinib mesylate).” NCT00183833 ↗ “Imatinib Mesylate intravenous solution” NCT04794088 ↗ “STI571 (imatinib mesylate) and BYL719” NCT01735968 ↗ “STI571 (imatinib mesylate) and BKM120” NCT01468688 ↗ “Glivec/Gleevec® (Imatinib Mesylate)” NCT01066468 ↗ “Glivec® (Imatinib Mesylate, STI571)” NCT00390897 ↗ “Gleevec, STI571(Imatinib Mesylate)” NCT00702689 ↗ “imatinib mesylate PO on days 15-28” NCT00061945 ↗ “Imatinib mesylate 100 mg (Glivec)” NCT00845221 ↗ “imatinib (imatinib mesylate)” NCT00702403 ↗ “imatinib mesylate (Gleevec)” NCT00258271 ↗ “Gleevec (Imatinib Mesylate)” NCT00354523 ↗ “Gleevec (Imatinib mesylate)” NCT00040105 ↗ “Imatinib Mesylate (Gleevec)” NCT00088231 ↗ “Gleevec (imatinib mesylate)” NCT00038194 ↗ “imatinib mesylate (STI571)” NCT00049569 ↗ “Imatinib mesylate (STI571)” NCT00027586 ↗ “Imatinib mesylate (Glivec)” NCT00278876 ↗ “Drug: Imatinib mesylate” NCT01545427 ↗ “Drug: Imatinib Mesylate” NCT01222013 ↗ “Drug: Imatinib mesylate” NCT00477269 ↗ “Drug: imatinib mesylate” NCT00323362 ↗ “Drug: imatinib mesylate” NCT00427999 ↗ “Drug: Imatinib Mesylate” NCT02177825 ↗ “Drug: Imatinib Mesylate” NCT04129931 ↗ “Drug: imatinib mesylate” NCT00049192 ↗ “Drug: Imatinib Mesylate” NCT03241199 ↗ “Drug: Imatinib Mesylate” NCT04006769 ↗ “Drug: Imatinib Mesylate” NCT02709083 ↗ “Drug: Imatinib Mesylate” NCT05623774 ↗ “Imatinib Mesylate (IM)” NCT00415909 ↗ |
| Known as | Imatinib Mesylate (Gleevec, STI571), NSC 716051, IND 61,135 | “Imatinib Mesylate (Gleevec, STI571), NSC 716051, IND 61,135” NCT00891527 ↗ |
| Known as | Impentri | “Intravenous Imatinib Mesylate (Impentri®)” NCT04794088 ↗ |
| Known as | Megavec | “Megavec 400 mg (Imatinib Mesylate) in Healthy Adult Male Volunteers” NCT01653314 ↗ |
| Known as | NCS 716051 | “Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas” NCT01673009 ↗ |
| Known as | NSC 716051 | “Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas” NCT01140360 ↗1“Imatinib Mesylate (Gleevec®; STI571; NSC #716051)” NCT01991379 ↗ |
| Known as | QTI571 | “A 24-week Randomized Placebo-controlled, Double-blind Multi-center Clinical Trial Evaluating the Efficacy and Safety of Oral QTI571 as an add-on Therapy in the Treatment of...” NCT00902174 ↗3“Treatment with imatinib resulted in improved hemodynamics and exercise capacity in a controlled trial (Imatinib [QTI571] in Pulmonary Arterial Hypertension, a Randomized...” PMID 26210752 ↗ Jun 2015 “An Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Oral QTI571 (Imatinib) in the Treatment of Severe Pulmonary Arterial Hypertension:...” NCT01117987 ↗ |
| Known as | STI571 | “A Phase I/II Study to Determine Safety and Efficacy of Arsenic Trioxide (Trisneox™) in Combination With Imatinib (STI571, Gleevec™) in Patients With Chronic Myelogenous...” NCT00081133 ↗44“This is a single center, four-treatment, four period, crossover study to evaluate the effect of food on the relative bioavailability of a single dose of imatinib (STI571) given...” NCT00422825 ↗ “PRIMARY OBJECTIVES: I. To assess the feasibility of a Southwest Oncology Group Phase II trial or oral STI-571/imatinib (Gleevec) administered to patients with metastatic or...” NCT00068783 ↗ “Open-label Multicenter Trial of Glivec® (Imatinib Mesylate, Formerly Known as STI571) in Combination With Chemotherapy (MTC) in Patients With Refractory or Relapsed Acute...” NCT00744081 ↗ “Phase I Trial of Fixed Dose STI571 (Imatinib Mesylate) With Escalating Doses of Docetaxel in Patients With Metastatic Androgen-Independent Prostate Cancer” NCT00038194 ↗ “A Phase I Trial of Imatinib Mesylate (Gleevec, Formerly Known as STI571) in Combination With Daunorubicin and Cytarabine for C-kit Positive Relapsed AML” NCT00268229 ↗ “Imatinib mesylate (STI571 or Gleevec) is a specific inhibitor of the fusion protein Bcr-Abl, the causal agent in chronic myelogenous leukaemia.” NCT00573326 ↗ “Phase II Study of Gleevec/Imatinib Mesylate (STI-571, NCS 716051) in Neurofibromatosis (NF1) Patients With Plexiform Neurofibromas” NCT01673009 ↗ “Pilot Study of Gleevec/Imatinib Mesylate (STI-571, NSC 716051) in Neurofibromatosis (NF1) Patient With Plexiform Neurofibromas” NCT01140360 ↗ “Phase I Study Of Flavopiridol In Combination With Imatinib Mesylate (STI571, Gleevec) In Bcr/Abl+ Hematological Malignancies” NCT00064285 ↗ “The goal of this clinical research study is to see if imatinib mesylate (Gleevec, STI571) can improve CML in chronic phase.” NCT00048672 ↗ “A phase I dose-escalation study of imatinib mesylate (Gleevec/STI571) plus capecitabine (Xeloda) in advanced solid tumors.” PMID 20530436 ↗ Apr 2010 “higher doses of imatinib mesylate (Gleevec, STI571) can improve chronic myelogenous leukemia (CML) in chronic phase.” NCT00038649 ↗ “Once daily oral administration of STI571 (Imatinib Mesylate) at a dose of 400 mg for 12 months.” NCT00022490 ↗ “Patients in cohorts 1 and 2 receive oral imatinib mesylate (STI571) once daily on days 1-28.” NCT00010049 ↗ “tyrosine kinase inhibitor imatinib mesylate (formerly STI 571, GLIVECÔ, Novartis Pharma)” NCT00510926 ↗ “tyrosine kinase inhibitor imatinib mesylate (formerly STI 571, GLIVEC, Novartis Pharma)” NCT00514488 ↗ “Glivec® (Imatinib mesylate, formerly known as STI 571) plus Gemzar® (Gemcitabine)” NCT00551252 ↗ “Glivec® (Imatinib, Formerly Known as STI571) to Produce a Biochemical Response” NCT01316458 ↗ “Imatinib Mesylate (Gleevec®, STI571) in Combination With Docetaxel (Taxotere)” NCT00216112 ↗ “Patients receive oral imatinib mesylate (STI-571) once daily for 9 months.” NCT00045422 ↗ “All subjects received in tablet form imatinib (STI571) 400 mg once daily.” NCT00867113 ↗ “Patients receive oral imatinib mesylate (STI571) once daily for 28 days.” NCT00004932 ↗ “Imatinib Mesylate (Gleevec; STI571), A PDGFR And C-Kit Inhibitor” NCT00039585 ↗ “tyrosine kinase inhibitor STI 571 (GLIVEC, Novartis Pharma)” NCT00511121 ↗ “Gleevec (Imatinib Mesylate, STI571) Maintenance Therapy” NCT00156286 ↗ “Imatinib Mesylate STI571 (Glivec®) Versus Placebo” NCT00479934 ↗ “Imatinib Mesylate (Gleevec®; STI571; NSC #716051)” NCT01991379 ↗ “STI571 (imatinib mesylate) and BYL719” NCT01735968 ↗ “Glivec® (Imatinib Mesylate, STI571)” NCT00390897 ↗ “Gleevec, STI571(Imatinib Mesylate)” NCT00702689 ↗ “STI571 (imatinib) 400mg po daily” NCT00427999 ↗ “imatinib mesylate (STI571)” NCT00049569 ↗ “Imatinib mesylate (STI571)” NCT00027586 ↗ “Drug: imatinib (STI571)” NCT00785785 ↗ “Imatinib (STI571)” NCT00514969 ↗ |
| Known as | Synthetic Tumor-Specific Breakpoint Peptide Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00267085 ↗ |
| Action | Inhibit | “Imatinib, a selective BCR-ABL1 kinase inhibitor” PMID 28273028 ↗ Mar 2017 |
| Modality | Small molecule | “Imatinib mesylate is a small molecule” PMID 19303137 ↗ Mar 2009 |
| Route | Oral | “Patients with Ph chromosome-positive status receive oral imatinib mesylate once daily for at least 28 days” NCT00002514 ↗ |
| Target | KIT | “Imatinib (STI571) inhibits a similar tyrosine kinase, BCR-ABL, leading to responses in chronic myeloid leukaemia, and has also been shown to inhibit KIT.” PMID 11705489 ↗ Oct 2001 |
| Target | PDGFRA | “Previous studies have shown that activating mutations of c-KIT/PDGFRA, potential therapeutic targets for imatinib mesylate, are implicated in the pathophysiology of...” PMID 15010069 ↗ Mar 2004 |